• Bill Williams, Ph.D


Thermokinetic compounding (KinetiSol®) is a novel manufacturing technology for making Amorphous Solid Dispersions of insoluble molecules to enhance their oral bio-availability that can outperform spray-drying and melt-extrusion. Here, we present case studies of partners’ experience with KinetiSol.


Moderator: Bill Williams, Ph.D.
Johnson & Johnson Centennial Chair and Division Head of Pharmaceutics, College of Pharmacy, The University of Texas at Austin; Editor-in-Chief of AAPS PharmSciTech; Editorial Advisory Board Member for Journal of Drug Delivery Science and Technology



9:20 – 9:50 am: "Use of the KinetiSol technology in non-clinical formulation development and comparison with other approaches" Keith Horspool, Ph.D., Vice President of Pharmaceutics, Boehringer-Ingelheim, United States.


9:50 – 10:00 am: Q&A with Keith


10:00 – 10:30 am: "Use of KinetiSol in the development of oncology assets" James Wesley, Ph.D., Senior Research Advisor at Eli Lilly and Company, United States.


10:30 – 10:40 am: Q&A with Jim


10:40 – 11:20 am "Case Studies on Enhancing Therapeutic Efficacy via Reformulation with KinetiSol" Dave A. Miller, Ph.D., Vice President of Research & Development, DisperSol Technologies, United States.


11:20 – 11:30 am Q&A with Dave


11:30 – 12:00 pm: Panel Discussion